Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
Net Income (Common)
Ascendis Pharma A/S
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Income (Common)
-€481.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Net Income (Common)
kr4.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
24%
|
CAGR 10-Years
44%
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Income (Common)
-kr703.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Income (Common)
kr1.5B
|
CAGR 3-Years
75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Bioporto A/S
CSE:BIOPOR
|
Net Income (Common)
-kr56.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
Saniona AB
STO:SANION
|
Net Income (Common)
-kr95.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
See Also
What is Ascendis Pharma A/S's Net Income (Common)?
Net Income (Common)
-481.4m
EUR
Based on the financial report for Dec 31, 2023, Ascendis Pharma A/S's Net Income (Common) amounts to -481.4m EUR.
What is Ascendis Pharma A/S's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-30%
Over the last year, the Net Income (Common) growth was 17%. The average annual Net Income (Common) growth rates for Ascendis Pharma A/S have been -5% over the past three years , -30% over the past five years .